Plasma Peptidylarginine Deiminase IV Promotes VWF-Platelet String Formation and Accelerates Thrombosis After Vessel Injury.


Journal

Circulation research
ISSN: 1524-4571
Titre abrégé: Circ Res
Pays: United States
ID NLM: 0047103

Informations de publication

Date de publication:
16 08 2019
Historique:
pubmed: 30 6 2019
medline: 9 7 2020
entrez: 29 6 2019
Statut: ppublish

Résumé

PAD4 (peptidylarginine deiminase type IV), an enzyme essential for neutrophil extracellular trap formation (NETosis), is released together with neutrophil extracellular traps into the extracellular milieu. It citrullinates histones and holds the potential to citrullinate other protein targets. While NETosis is implicated in thrombosis, the impact of the released PAD4 is unknown. This study tests the hypothesis that extracellular PAD4, released during inflammatory responses, citrullinates plasma proteins, thus affecting thrombus formation. Here, we show that injection of r-huPAD4 in vivo induces the formation of VWF (von Willebrand factor)-platelet strings in mesenteric venules and that this is dependent on PAD4 enzymatic activity. VWF-platelet strings are naturally cleaved by ADAMTS13 (a disintegrin and metalloproteinase with thrombospondin type-1 motif-13). We detected a reduction of endogenous ADAMTS13 activity in the plasma of wild-type mice injected with r-huPAD4. Using mass spectrometry and in vitro studies, we found that r-huPAD4 citrullinates ADAMTS13 on specific arginine residues and that this modification dramatically inhibits ADAMTS13 enzymatic activity. Elevated citrullination of ADAMTS13 was observed in plasma samples of patients with sepsis or noninfected patients who were elderly (eg, age >65 years) and had underlying comorbidities (eg, diabetes mellitus and hypertension) as compared with healthy donors. This shows that ADAMTS13 is citrullinated in vivo. VWF-platelet strings that form on venules of Adamts13 Our data indicate that PAD4 in circulation reduces VWF-platelet string clearance and accelerates the formation of a stable platelet plug after vessel injury. We propose that this effect is, at least in part, due to ADAMTS13 inhibition.

Identifiants

pubmed: 31248335
doi: 10.1161/CIRCRESAHA.118.314571
pmc: PMC6697196
mid: NIHMS1533066
doi:

Substances chimiques

von Willebrand Factor 0
Protein-Arginine Deiminase Type 4 EC 3.5.3.15
peptidylarginine deiminase 4, mouse EC 3.5.3.15

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

507-519

Subventions

Organisme : NHLBI NIH HHS
ID : HHSN268201000031C
Pays : United States
Organisme : NIGMS NIH HHS
ID : P41 GM104603
Pays : United States
Organisme : NHLBI NIH HHS
ID : R35 HL135765
Pays : United States
Organisme : NIGMS NIH HHS
ID : F32 GM128231
Pays : United States
Organisme : NIGMS NIH HHS
ID : P01 GM109767
Pays : United States
Organisme : NIGMS NIH HHS
ID : R35 GM118112
Pays : United States

Commentaires et corrections

Type : CommentIn

Références

Blood. 2002 Dec 1;100(12):4033-9
pubmed: 12393397
Blood. 2005 Feb 1;105(3):1085-93
pubmed: 15388580
J Neurosci Res. 2005 Apr 1;80(1):120-8
pubmed: 15704193
Br J Haematol. 2005 Apr;129(1):93-100
pubmed: 15801961
Blood. 2006 Jan 15;107(2):528-34
pubmed: 16189276
J Exp Med. 2006 Mar 20;203(3):767-76
pubmed: 16533881
Biochemistry. 2006 Oct 3;45(39):11727-36
pubmed: 17002273
Blood. 2007 Mar 15;109(6):2424-9
pubmed: 17119108
Anal Biochem. 2007 Oct 15;369(2):232-40
pubmed: 17716614
Blood. 2008 Aug 15;112(4):957-64
pubmed: 18344423
J Exp Med. 2008 Sep 1;205(9):2065-74
pubmed: 18695007
BMC Cancer. 2009 Jan 30;9:40
pubmed: 19183436
J Am Soc Mass Spectrom. 2009 Apr;20(4):723-7
pubmed: 19200748
Blood. 2009 Oct 8;114(15):3329-34
pubmed: 19687510
Histol Histopathol. 2009 Nov;24(11):1391-8
pubmed: 19760588
FEBS J. 2009 Nov;276(22):6763-72
pubmed: 19843180
Nat Med. 2009 Nov;15(11):1318-21
pubmed: 19855397
Blood. 2010 Oct 21;116(16):3064-72
pubmed: 20647566
Proc Natl Acad Sci U S A. 2010 Sep 7;107(36):15880-5
pubmed: 20798043
Blood. 2011 Jan 27;117(4):1400-7
pubmed: 20959603
Proteomics Clin Appl. 2010 May;4(5):511-8
pubmed: 21137068
J Immunol. 2011 Apr 1;186(7):4396-404
pubmed: 21346230
Biochemistry. 2011 May 17;50(19):3997-4010
pubmed: 21466234
Arterioscler Thromb Vasc Biol. 2012 Aug;32(8):1777-83
pubmed: 22652600
Blood. 2012 Dec 20;120(26):5217-23
pubmed: 22915644
Front Immunol. 2012 Oct 04;3:307
pubmed: 23060885
BMC Cancer. 2012 Oct 30;12:500
pubmed: 23110523
Nat Rev Immunol. 2013 Jan;13(1):34-45
pubmed: 23222502
Proc Natl Acad Sci U S A. 2013 May 21;110(21):8674-9
pubmed: 23650392
Arterioscler Thromb Vasc Biol. 2013 Aug;33(8):2032-2040
pubmed: 23818485
J Vasc Surg Venous Lymphat Disord. 2013 Oct 1;1(4):
pubmed: 24187669
J Thromb Haemost. 2014 Jun;12(6):860-70
pubmed: 24674135
Arterioscler Thromb Vasc Biol. 2014 Jul;34(7):1382-9
pubmed: 24790143
Surgery. 2014 Aug;156(2):229-34
pubmed: 24957671
Blood Rev. 2014 Nov;28(6):227-34
pubmed: 25213289
Acta Diabetol. 2015 Jun;52(3):497-503
pubmed: 25387570
J Biol Chem. 2015 Jan 16;290(3):1422-31
pubmed: 25422322
Thromb Haemost. 2015 Apr;113(4):708-18
pubmed: 25503977
Curr Drug Targets. 2015;16(7):700-10
pubmed: 25642720
Nat Med. 2015 Jul;21(7):815-9
pubmed: 26076037
Arthritis Rheumatol. 2015 Dec;67(12):3135-45
pubmed: 26245941
ACS Chem Biol. 2015 Nov 20;10(11):2520-8
pubmed: 26360112
Clin Rheumatol. 2016 May;35(5):1181-8
pubmed: 26415740
Blood. 2015 Dec 17;126(25):2739-46
pubmed: 26511134
Blood Rev. 2016 Jul;30(4):257-61
pubmed: 26776504
Medicine (Baltimore). 2016 Apr;95(16):e3374
pubmed: 27100422
Blood. 2016 Jul 14;128(2):277-85
pubmed: 27106123
Sci Rep. 2016 May 23;6:26430
pubmed: 27210478
Shock. 2017 Mar;47(3):313-317
pubmed: 27488091
Curr Opin Hematol. 2017 Jan;24(1):66-71
pubmed: 27820735
J Exp Med. 2017 Feb;214(2):439-458
pubmed: 28031479
Bioorg Med Chem. 2017 May 1;25(9):2643-2656
pubmed: 28341402
Nat Rev Dis Primers. 2017 Apr 06;3:17020
pubmed: 28382967
PLoS One. 2017 Jun 7;12(6):e0179258
pubmed: 28591212
Thromb Haemost. 2018 Jan;118(1):28-41
pubmed: 29304523
J Am Heart Assoc. 2018 Jan 24;7(3):
pubmed: 29367415
Mol Cell Proteomics. 2018 Jul;17(7):1378-1391
pubmed: 29610271
Cell Chem Biol. 2018 Jun 21;25(6):691-704.e6
pubmed: 29628436
Sci Rep. 2018 Apr 10;8(1):5791
pubmed: 29636514
Blood. 2018 Jul 12;132(2):141-147
pubmed: 29866815
FASEB J. 2018 Jun 20;:fj201800691R
pubmed: 29924943
Crit Care. 2018 Jul 13;22(1):176
pubmed: 30005596
J Cell Mol Med. 2018 Oct;22(10):4732-4737
pubmed: 30044533
ACS Chem Biol. 2018 Sep 21;13(9):2663-2672
pubmed: 30044909
J Thromb Haemost. 2019 Jan;17(1):6-18
pubmed: 30375718
Cell. 1986 Jul 18;46(2):185-90
pubmed: 3087627
J Cell Biol. 1982 Oct;95(1):355-60
pubmed: 6754744

Auteurs

Nicoletta Sorvillo (N)

From the Program in Cellular and Molecular Medicine (N.S., D.M.M., K.M., D.C., C.S., D.D.W.), Boston Children's Hospital, MA.
Department of Pediatrics, Harvard Medical School, Boston, MA (N.S., D.M.M., K.M., D.C., D.D.W.).

Daniella M Mizurini (DM)

From the Program in Cellular and Molecular Medicine (N.S., D.M.M., K.M., D.C., C.S., D.D.W.), Boston Children's Hospital, MA.
Department of Pediatrics, Harvard Medical School, Boston, MA (N.S., D.M.M., K.M., D.C., D.D.W.).

Carmen Coxon (C)

Target Discovery Institute, University of Oxford, NDM Research Building, Headington, United Kingdom (C.C.).

Kimberly Martinod (K)

From the Program in Cellular and Molecular Medicine (N.S., D.M.M., K.M., D.C., C.S., D.D.W.), Boston Children's Hospital, MA.
Department of Pediatrics, Harvard Medical School, Boston, MA (N.S., D.M.M., K.M., D.C., D.D.W.).

Ronak Tilvawala (R)

Department of Biochemistry and Molecular Pharmacology, UMass Medical School, Worcester, MA (R.T., A.J.S., P.R.T.).

Deya Cherpokova (D)

From the Program in Cellular and Molecular Medicine (N.S., D.M.M., K.M., D.C., C.S., D.D.W.), Boston Children's Hospital, MA.
Department of Pediatrics, Harvard Medical School, Boston, MA (N.S., D.M.M., K.M., D.C., D.D.W.).

Ari J Salinger (AJ)

Department of Biochemistry and Molecular Pharmacology, UMass Medical School, Worcester, MA (R.T., A.J.S., P.R.T.).

Robert J Seward (RJ)

Department of Biochemistry, Center for Biomedical Mass Spectrometry, Boston University School of Medicine, MA (R.J.S., C.E.C.).

Caleb Staudinger (C)

From the Program in Cellular and Molecular Medicine (N.S., D.M.M., K.M., D.C., C.S., D.D.W.), Boston Children's Hospital, MA.

Eranthie Weerapana (E)

Department of Chemistry, Boston College, Chestnut Hill, MA (E.W.).

Nathan I Shapiro (NI)

Department of Emergency Medicine, Harvard Medical School, Beth Israel Deaconess Medical Center, Boston, MA (N.I.S.).

Catherine E Costello (CE)

Department of Biochemistry, Center for Biomedical Mass Spectrometry, Boston University School of Medicine, MA (R.J.S., C.E.C.).

Paul R Thompson (PR)

Department of Biochemistry and Molecular Pharmacology, UMass Medical School, Worcester, MA (R.T., A.J.S., P.R.T.).

Denisa D Wagner (DD)

From the Program in Cellular and Molecular Medicine (N.S., D.M.M., K.M., D.C., C.S., D.D.W.), Boston Children's Hospital, MA.
Division of Hematology/Oncology (D.D.W.), Boston Children's Hospital, MA.
Department of Pediatrics, Harvard Medical School, Boston, MA (N.S., D.M.M., K.M., D.C., D.D.W.).

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH